Sam Chun Dang Pharm. Co., Ltd
Financials
Valuation Metrics
Sam Chun Dang Pharm. Co., Ltd's Market Cap is ₩3.7T. At end of 2025 it was ₩5.5T. Ranked #128 of 2,421 in KR market (top 5%), #14 of 1,640 on KOSDAQ (top 0.9%), #8 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.74T KRW | KR#128/2,421 Sec#8/231 |
| Revenue | 259.90B KRW | KR#898/2,421 Sec#44/231 |
| Net Income | 25.47B KRW | KR#615/2,421 Sec#37/231 |
| Total Assets | 575.39B KRW | KR#706/2,421 Sec#38/231 |
| Net Assets | 400.79B KRW | KR#594/2,421 Sec#37/231 |
| Employees | 417 | KR#585/2,421 Sec#49/231 |
| Value | ||
| P/E | 146.96x | KR#1,506/2,421 Sec#103/231 |
| P/B | 9.34x | KR#2,343/2,421 Sec#207/231 |
| P/S | 14.40x | KR#2,312/2,421 Sec#173/231 |
| EV/EBITDA | 211.59x | KR#1,534/2,421 Sec#106/231 |
| FCF Yield | -0.97% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 6.36% | KR#943/2,421 Sec#65/231 |
| ROA | 4.43% | KR#803/2,421 Sec#63/231 |
| Op. Margin | 6.83% | KR#744/2,421 Sec#61/231 |
| Revenue Growth | 20.83% | KR#535/2,421 Sec#50/231 |
| Financial Health | ||
| Debt Ratio | 43.57% | KR#862/2,421 Sec#100/231 |
| Total Debt | 74.15B KRW | KR#839/2,421 Sec#56/231 |
| FCF | -36.35B KRW | KR#2,023/2,421 Sec#197/231 |
| Cash | 63.02B KRW | KR#652/2,421 Sec#35/231 |
| Current Ratio | 2.21x | KR#792/2,421 Sec#93/231 |
| Net Debt/EBITDA | 0.63x | KR#695/2,421 Sec#43/231 |
| Dividend | ||
| Div. Yield | 0.03% | KR#1,380/2,421 Sec#86/231 |
| Div. Growth | -75.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -26.45% | KR#1,451/2,421 Sec#109/231 |
| 1M Return | -11.14% | KR#2,143/2,421 Sec#179/231 |
| From 52W High | -87.06% | KR#2,396/2,421 Sec#229/231 |
| 1Y MDD | -89.32% | KR#2,401/2,421 Sec#230/231 |
| Trading | ||
| Volume | 46,681 shares | KR#1,168/2,421 Sec#115/231 |
| Trading Value | 7.51B KRW | KR#289/2,421 Sec#25/231 |
| Foreign Own. | 4.77% | KR#897/2,421 Sec#80/231 |
| Per Share | ||
| EPS | 1,086 KRW | KR#692/2,421 Sec#46/231 |
| BPS | 17,086 KRW | KR#620/2,421 Sec#41/231 |
Company Info
Samchundang Pharm, established in 1943 and headquartered in Hwaseong-si, Gyeonggi-do, began as a pharmaceutical manufacturer and seller. By acquiring Optus Pharm in 2013, it became a leading specialized ophthalmic treatment company, producing prescription-based pharmaceuticals including antibiotics, circulatory disease treatments, digestive disease treatments, and eye drops. The company is actively expanding its global market presence by exporting finished pharmaceuticals to Vietnam, Hong Kong, and Singapore.